Drugs / PEG-rhGH
PEG-rhGH
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06385145 | May → Jul 2024 | pituitary deficiency | Changchun GeneScience Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06135155 | Nov → Dec 2023 | pituitary deficiency | Changchun GeneScience Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06135168 | Oct → Nov 2023 | pituitary deficiency | Changchun GeneScience Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07260500 | Nov 2025 → Dec 2026 expected | fetal growth restriction | Changchun GeneScience Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT03189160 | Mar 2016 → Mar 2018 | Turner syndrome | Changchun GeneScience Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT05144035 | Apr 2022 → Dec 2025 | cognitive disorder, fetal growth restriction | Tongji Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT06863363 | — | obesity disorder | Shanghai Zhongshan Hospital | Not yet recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06768411 | Jan 2025 → Dec 2026 expected | isolated short stature | Second Affiliated Hospital of Wenzhou Medical University | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PEG-rhGH | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03189160 ↗ |
| Known as | PEG-rhGH Injection | “Polyethylene Glycol Recombinant Human Growth Hormone Injection (PEG-rhGH Injection), 54 IU/9.0 mg/1.0 mL/amp.;” NCT06863363 ↗ |
| Known as | Polyethylene Glycol Recombinant Human Growth Hormone Injection | “Polyethylene Glycol Recombinant Human Growth Hormone Injection (PEG-rhGH Injection), 54 IU/9.0 mg/1.0 mL/amp.;” NCT06863363 ↗ |
| Modality | Protein / enzyme biologic | “pegylated recombinant human growth hormone (PEG-rhGH) injection” NCT03189160 ↗ |
| Route | Subcutaneous | “0.1 mg/kg/w by subcutaneous injection for 52 weeks.” NCT03189160 ↗ |